GlassScriptPhysician profile
Paul Robert Glowienka
NPI 1497753925
$10,620.55
in general payments reported to CMS, 2019-2025
39 companies · $30.64 in 2025
The $30.64 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,910 · 2020: $2,207 · 2021: $3,517 · 2022: $1,931 · 2024: $24.25 · 2025: $30.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $54.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $54.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,433.60 | 2019-2022 | |
| Medtronic, INC. | $1,351.30 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Abbott Laboratories | $874.13 | 2019-2022 | |
| Amgen INC. | $778.72 | 2019-2022 | |
| Lilly USA, LLC | $610.01 | 2019-2022 | |
| Medtronic Minimed, INC. | $438.03 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $419.14 | 2019-2021 | |
| Amarin Pharma, INC. | $405.44 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.08 | 2019-2022 | |
| Antares Pharma, INC. | $354.90 | 2019-2022 | |
| Corcept Therapeutics | $293.75 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $287.91 | 2019-2021 | |
| Insulet Corporation | $286.04 | 2019-2022 | |
| Dexcom, INC. | $278.83 | 2021-2022 | |
| Zealand Pharma US, INC. | $270.16 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Glowienka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.